<?xml version="1.0" encoding="UTF-8"?>
<p>The release of new viruses from the host cell is the final step of the virus infection cycle. Some drugs inhibit this phase through acting on the viral protein involved in such a process, which have been approved for the treatment of InfV infection (
 <xref rid="B75" ref-type="bibr">Hayden et al., 1997</xref>; 
 <xref rid="B68" ref-type="bibr">Gubareva et al., 2000</xref>). The haemagglutinin of InfV A and B viruses bind to receptors with neuraminic acid (
 <xref rid="B68" ref-type="bibr">Gubareva et al., 2000</xref>). The neuraminidase (NA) enzymatic activity promotes the release of viruses by removing neuraminic acids from oligosaccharide chains of receptors (
 <xref rid="B26" ref-type="bibr">Colman, 1994</xref>). In addition to previously introduced M2 ion channel inhibitors, neuraminidase inhibitors (NAIs) are another class of anti-InfV drugs currently available (
 <xref rid="B36" ref-type="bibr">De Clercq, 2006</xref>). Most of the antiviral agents not only inhibit viral replication but also alter cellular metabolism, which creates the toxicity.
</p>
